Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.37 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 6/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1E | P28566 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1485145 | 1.00 | SLC6A1 (0.37) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL16776488 | 1.00 | SLC6A1 (0.37) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL22691463 | 0.98 | SLC6A1 (0.35) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3249707 | 0.98 | SLC6A1 (0.35) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL4096912 | 0.84 | — | — | |
| SCHEMBL512534 | 0.84 | — | — | |
| SCHEMBL1484930 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL26598349 | 0.82 | HTR2C (0.32) | HTR2C | |
| Ammonia Solution, Strong SCHEMBL17713293 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL26598105 | 0.82 | HTR2C (0.32) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 540 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118561742-A | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2024-08-30 | — | — | CN | claimed |
| CN-102702080-B | Preparation method of 3-trifluoromethyl piperidine derivatives | YANGZHOU FUYAO TECHNOLOGY CO LTD | 2014-02-19 | — | — | CN | claimed |
| CN-102702080-A | Preparation method of 3-trifluoromethyl piperidine derivatives | YANGZHOU FUYAO TECHNOLOGY CO LTD | 2012-10-03 | — | — | CN | claimed |
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-12-16 | — | — | US | claimed |
| CN-101484424-A | Therapeutic compounds | HELICON THERAPEUTICS INC (US) | 2009-07-15 | — | — | CN | claimed |
| US-20090118286-A1 | Heterobicyclic Acrylamides | BAYER CROPSCIENCE AG (DE) | 2009-05-07 | — | — | US | claimed |
| US-20080293674-A1 | Azinyl Imidazoazine and Azinyl Carboxamide | BAYER CROPSCIENCE AG (DE) | 2008-11-27 | — | — | US | claimed |
| EP-1989185-A1 | THERAPEUTIC COMPOUNDS | Helicon Therapeutics, Inc. (US) | 2008-11-12 | — | — | EP | claimed |
| CN-101171255-A | Heterobicyclic acrylamides | BAYER CROPSCIENCE AG (DE) | 2008-04-30 | — | — | CN | claimed |
| EP-1858899-A1 | HETEROBICYCLIC ACRYLAMIDES | Bayer CropScience AG (DE) | 2007-11-28 | — | — | EP | claimed |
| WO-2007100851-A1 | THERAPEUTIC COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2007-09-07 | — | — | WO | claimed |
| US-20070203154-A1 | Therapeutic Compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | claimed |
| CN-1980926-A | Azinyl imidazoazine and azinyl carboxamide | BAYER CROPSCIENCE AG (DE) | 2007-06-13 | — | — | CN | claimed |
| EP-1751152-A2 | AZINYL IMIDAZOAZINE AND AZINYL CARBOXAMIDE | Bayer CropScience Aktiengesellschaft (DE) | 2007-02-14 | — | — | EP | claimed |
| WO-2006094666-A1 | HETEROBICYCLIC ACRYLAMIDES | BAYER CROPSCIENCE AG (DE) | 2006-09-14 | — | — | WO | claimed |
| WO-2005113553-A2 | AZINYL IMIDAZOAZINE AND AZINYL CARBOXAMIDE | BAYER CROPSCIENCE AG (DE) | 2005-12-01 | — | — | WO | claimed |
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4736856-A2 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20040110746-A1 | Piperazinyl and diazapanyl benzamides and benzthioamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-10 | — | — | US | disclosed |
| WO-2004037801-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293674-A1 | Azinyl Imidazoazine and Azinyl Carboxamide | AZI2, NISCH, ZYX | SLC6A1 2625/4885SLC6A11 3618/4885TSHR 3493/4885 |
| US-20100317648-A1 | THERAPEUTIC COMPOUNDS | MAOB, MAOA, HTR1B | SLC6A1 669/4885SLC6A11 1221/4885TSHR 939/4885 |
| US-20040110746-A1 | Piperazinyl and diazapanyl benzamides and benzthioamides | HRH2, HNMT, HRH3 | SLC6A1 951/4885SLC6A11 648/4885TSHR 1600/4885 |
| US-20090118286-A1 | Heterobicyclic Acrylamides | CCNB1, C3AR1, CCNA2 | SLC6A1 3408/4885SLC6A11 3879/4885TSHR 982/4885 |
| US-20070203154-A1 | Therapeutic Compounds | MAOB, MAOA, HTR1B | SLC6A1 669/4885SLC6A11 1221/4885TSHR 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.